Catch your breath: Tests of exhaled breath may help diagnose pulmonary nodules

lung - 61.74 Kb
Breath testing could be used to discriminate between benign and malignant pulmonary nodules, according to a pilot study published in the October issue of the Journal of Thoracic Oncology.

The testing method developed and studied by researchers Hossam Haick, PhD, and colleagues from the Technion-Israel Institute of Technology in Haifa, Israel, could bypass some problems inherent with CT screening.

Haick and colleagues studied 74 patients who were under investigation for pulmonary nodules and attended a referral clinic located in Colorado between March 2009 and May 2010. Exhaled breath was collected from each patient and analyzed using gas chromatography with mass spectrometry and information from chemical nanoarrays. Final diagnosis was confirmed using bronchoscopy, wedge resection and/or lobectomy.

Both the gas chromatography and nanoarray testing methods were able to accurately identify 53 malignant pulmonary nodules. Another 19 nodules were shown correctly by the techniques to be benign, which for this study was defined as nodules that either regressed or remained stable over a 24-month period.

The nanoarrays technique also was shown to discriminate between adenocarcinoma and squamous cell carcinoma, and between early versus advanced disease.

Haick and colleagues wrote that, “the reported breath test in this study could have significant impact on reducing unnecessary investigation and reducing the risk of procedure-related morbidity and costs. In addition, it could facilitate faster therapeutic intervention, replacing time-consuming clinical follow-up that would eventually lead to the same intervention."

Breath testing could serve as a secondary screening test for patients found to have pulmonary nodules on CT. Low-dose CT screening reduces mortality rates by 20 percent, however, with a false positive rate of 96 percent, many patients undergo invasive procedures following CT screening only to find their pulmonary nodules are not cancerous.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.